Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling

被引:21
作者
Saber, Sameh [1 ]
Abd El-Fattah, Eslam E. [2 ]
Abdelhamid, Amir Mohamed [1 ]
Mourad, Ahmed A. E. [3 ]
Hamouda, Manal Ali Mahrous [4 ]
Elrabat, Amr [5 ]
Zakaria, Sahar [6 ]
Haleem, Amira A. [7 ]
Mohamed, Sherin Z. [8 ]
Elgharabawy, Rehab Mohamed [9 ]
Morsy, Nesreen Elsayed [10 ]
Khalaf, Noura El Adle [11 ]
Mohammed, Osama A. [12 ]
El-Bahouty, Waleed Barakat [13 ]
Mostafa, Sally Abdallah [7 ]
Abdelhady, Rasha [14 ]
Galal, Omneya [15 ]
ElSaid, Zeinab H. [16 ]
Yahya, Galal [17 ]
Shata, Ahmed [11 ,18 ]
Youssef, Mahmoud E. [1 ]
机构
[1] Delta Univ Sci & Technol, Fac Pharm, Dept Pharmacol, Gamasa 11152, Egypt
[2] Delta Univ Sci & Technol, Fac Pharm, Dept Biochem, Gamasa 11152, Egypt
[3] Port Said Univ, Fac Pharm, Pharmacol & Toxicol Dept, Port Said 42511, Egypt
[4] Menoufia Univ, Clin Pharm Dept, Fac Pharm, Menoufia 32511, Egypt
[5] Mansoura Univ, Fac Med, Gastroenterol & Hepatol Dept, Mansoura 35516, Egypt
[6] Mansoura Univ, Fac Med, Dept Trop Med, Mansoura 35516, Egypt
[7] Mansoura Univ, Fac Med, Med Biochem & Mol Biol Dept, Mansoura 35516, Egypt
[8] Horus Univ, Fac Med, Dept Internal Med, New Damietta 34518, Egypt
[9] Tanta Univ, Fac Pharm, Pharmacol & Toxicol Dept, Tanta 31527, Egypt
[10] Mansoura Univ, Mansoura Univ Sleep Ctr, Fac Med, Pulm Med Dept, Mansoura 35516, Egypt
[11] Mansoura Univ, Fac Med, Dept Clin Pharmacol, Mansoura 35516, Egypt
[12] Ain Shams Univ, Fac Med, Dept Clin Pharmacol, Cairo 11566, Egypt
[13] Tanta Univ, Fac Med, Pharmacol Dept, Tanta 31527, Egypt
[14] Fayoum Univ, Fac Pharm, Pharmacol & Toxicol Dept, Al Fayyum, Egypt
[15] Ahram Canadian Univ, Fac Pharm, Dept Pharmacol, Giza 12451, Egypt
[16] Mansoura Univ, Fac Med, Dept Med Physiol, Mansoura 35516, Egypt
[17] Zagazig Univ, Fac Pharm, Dept Microbiol & Immunol, Al Sharqia 44519, Egypt
[18] Delta Univ Sci & Technol, Fac Pharm, Dept Clin Pharm, Gamasa 11152, Egypt
关键词
Hepatocellular carcinoma; Nifuroxazide; 17-DMAG; HSP90; STAT3; HIF-1; LIVER NEOPLASTIC CHANGES; OXIDATIVE STRESS; 17-DMAG; STAT3; HIF-1-ALPHA; EXPRESSION; HYPOXIA; RATS; ACTIVATION; PATHWAY;
D O I
10.1016/j.biopha.2022.114196
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hepatocellular carcinoma (HCC) is the third foremost cause of cancer-related deaths. HCC has a very bad prognosis because it is asymptomatic in the early stages, resulting in a late diagnosis, and it is highly resistant to conventional chemotherapy. Such chemotherapies have been proven disappointing because they provide extremely low survival benefits. This study discloses that the STAT3/HIF-1 alpha is an auspicious therapeutic attack site for conceivable repression of HCC development. A site that can be targeted by simultaneous administration of a STAT3 inhibitor in the context of HSP90 inhibition. 17-DMAG binds to HSP90 and constrains its function, resulting in the degradation of HSP90 client proteins HIF-1 alpha and STAT3. Hypoxia recruits STAT3/HIF-1 alpha complex within the VEGF promoter. Additionally, it was acknowledged that STAT3 is an essential mediator of VEGF transcription by direct binding to its promoter. Furthermore, it induces HIF-1 alpha stability and enhances its transcriptional activity. Herein, we revealed that the combination therapy using 17-DMAG and nifuroxazide, a STAT3 inhibitor, repressed the diethylnitrosamine-induced alterations in the structure of the liver. This effect was mediated via decreasing the levels of the HSP90 client proteins HIF-1 alpha and pSTAT3 resulting in the sup-pression of the STAT3/HIF-1 alpha complex transcriptional activity. To conclude, 17-DMAG/NFXZD combination therapy-induced disruption in the STAT3/HIF-1 alpha loop led to a potential antiangiogenic activity and showed apoptotic potential by inhibiting autophagy and inducing ROS/apoptosis signaling. Additionally, this combi-nation therapy exhibited promising survival prolongation in mice with HCC. Consequently, the use of 17-DMAG/ NFXZD renders an inspirational perspective in managing HCC. However, further investigations are compulsory.
引用
收藏
页数:14
相关论文
共 50 条
[41]   Schisanhenol Inhibits the Proliferation of Hepatocellular Carcinoma Cells by Targeting Programmed Cell Death-ligand 1 via the STAT3 Pathways [J].
Zhang, Zhihong ;
Zhong, Yiwen ;
Han, Xu ;
Hu, Xueyang ;
Wang, Yuhan ;
Huang, Lei ;
Li, Siying ;
Li, Ziqing ;
Wang, Chunmei ;
Li, He ;
Sun, Jinghui ;
Zhuang, Wenyue ;
Wang, Mengyang ;
Chen, Jianguang ;
Liu, Wei ;
Liu, Chang ;
Guo, Xin ;
Yuan, Siyu ;
Wu, Jiping .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2025, 25 (10) :697-710
[42]   Role of the HIF-1α/BNIP3 Signaling Pathway in Recurrent Hepatocellular Carcinoma and the Mechanism of Traditional Chinese Medicine [J].
Liu, Sizhe ;
Kang, Le ;
Song, Yagang ;
Miao, Mingsan .
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 :893-908
[43]   Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells [J].
Yang, Jie ;
Cai, Xueting ;
Lu, Wuguang ;
Hu, Chunping ;
Xu, Xiaojun ;
Yu, Qiang ;
Cao, Peng .
CANCER LETTERS, 2013, 328 (02) :243-251
[44]   Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1α and STAT3 Pathways [J].
Godse, Pallavi ;
Kumar, Pramod ;
Yewalkar, Nilambari ;
Deore, Vijaykumar ;
Lohar, Manoj ;
Mundada, Ramswaroop ;
Padgaonkar, Amol ;
Manohar, Sonal ;
Joshi, Asavari ;
Bhatia, Dimple ;
Desai, Nikesh ;
Damre, Anagha ;
Bhonde, Mandar ;
Joshi, Kalpana ;
Sharma, Rajiv ;
Kumar, Sanjay .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (09) :1460-1466
[45]   Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3 [J].
Dai, Xiaoyun ;
Ahn, Kwang Seok ;
Kim, Chulwon ;
Siveen, Kodappully Sivaraman ;
Ong, Tina H. ;
Shanmugam, Muthu K. ;
Li, Feng ;
Shi, Jizhong ;
Kumar, Alan Prem ;
Wang, Ling Zhi ;
Goh, Boon Cher ;
Magae, Junji ;
Hui, Kam M. ;
Sethi, Gautam .
MOLECULAR ONCOLOGY, 2015, 9 (04) :818-833
[46]   NAD(P)HX epimerase downregulation promotes tumor progression through ROS/HIF-1α signaling in hepatocellular carcinoma [J].
Sun, Bo ;
Yu, Lei ;
Xu, Cong ;
Li, Yi-Ming ;
Zhao, Yan-Rong ;
Cao, Mo-Mo ;
Yang, Lian-Yue .
CANCER SCIENCE, 2021, 112 (07) :2753-2769
[47]   miR-20b Modulates VEGF Expression by Targeting HIF-1α and STAT3 in MCF-7 Breast Cancer Cells [J].
Cascio, Sandra ;
D'Andrea, Aleco ;
Ferla, Rita ;
Surmacz, Eva ;
Gulotta, Eliana ;
Amodeo, Valeria ;
Bazan, Viviana ;
Gebbi, Nicola ;
Russo, Antonio .
JOURNAL OF CELLULAR PHYSIOLOGY, 2010, 224 (01) :242-249
[48]   The role and mechanism of HIF-1α-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma [J].
Wang, Pingfeng ;
Tong, Kun ;
Li, Ying ;
Li, Xuejie ;
Zhang, Yuan ;
Gu, Jiangxue ;
Lei, Panwei ;
Yan, Shirong ;
Hu, Pei .
CELLULAR SIGNALLING, 2024, 114
[49]   Morusin Reverses Epithelial-Mesenchymal Transition in Gallbladder Cancer Cells by Regulating STAT3/HIF-1α Signaling [J].
Ji, Lichao ;
Chai, Yingjie ;
Tong, Chenhao ;
Hu, Yanxin ;
Li, Jiandong ;
Lu, Baochun ;
Yu, Jianhua .
CHEMICAL BIOLOGY & DRUG DESIGN, 2025, 105 (01)
[50]   GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells [J].
Yue, Xin ;
Zhao, Peiwei ;
Wu, Kongming ;
Huang, Juan ;
Zhang, Wen ;
Wu, Yaogui ;
Liang, Xiaohui ;
He, Xuelian .
TUMOR BIOLOGY, 2016, 37 (07) :9789-9796